Burzynski Research Institute (BZYR) Common Equity (2011 - 2025)
Burzynski Research Institute (BZYR) posted Common Equity of -$67343.0 for Q4 2025, up 3.2% sequentially from -$69571.0 in Q3 2025, and down 215.78% YoY from $58165.2 in Q4 2024.
Burzynski Research Institute (BZYR) Common Equity (2011 - 2025) Analysis & Trends
Burzynski Research Institute has reported Common Equity for 15 years, with the latest figure at -$67343.0 in Q4 2025.
- Quarterly Common Equity fell 215.78% year-over-year to -$67343.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was -$67343.0 (down 215.78% YoY) and the FY2025 annual result came in at -$41637.0, down 65.73% from the prior year.
- Common Equity improved to -$67343.0 in Q4 2025 per BZYR's latest filing, from -$69571.0 in the prior quarter.
- Over five years, Common Equity peaked at $5350.0 in Q4 2021 and troughed at -$127868.0 in Q2 2024.
- A 5-year average of -$42053.5 and a median of -$36757.0 in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2024: Common Equity jumped 104.15% in 2021, then sank 1857.86% in 2024.
- Over 5 years, Common Equity stood at $5350.0 in 2021, then tumbled by 597.72% to -$26628.0 in 2022, then slumped by 30.82% to -$34834.0 in 2023, then surged by 38.78% to -$21326.0 in 2024, then slumped by 215.78% to -$67343.0 in 2025.
- According to Business Quant data, Common Equity over the past three periods registered -$67343.0, -$69571.0, and -$69716.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | -67,343.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | -67,343.00 |
| Aug 31, 2025 | -69,571.00 |
| May 31, 2025 | -69,716.00 |
| Feb 28, 2025 | -41,637.00 |
| Nov 30, 2024 | -21,326.00 |
| Aug 31, 2024 | -87,634.00 |
| May 31, 2024 | -127,868.00 |
| Feb 29, 2024 | -25,123.00 |
| Nov 30, 2023 | -34,834.00 |
| Aug 31, 2023 | -4,476.00 |
| May 31, 2023 | -70,518.00 |
| Feb 28, 2023 | -13,727.00 |
| Nov 30, 2022 | -26,628.00 |
| Aug 31, 2022 | -13,638.00 |
| May 31, 2022 | -38,680.00 |
| Feb 28, 2022 | 1,206.00 |
| Nov 30, 2021 | 5,350.00 |
| Aug 31, 2021 | -27,831.00 |
| May 31, 2021 | -61,233.00 |
| Feb 28, 2021 | -45,843.00 |